AstraZeneca Plc to increase Dividend by 7% for 2024

AZN

AstraZeneca plc (LON:AZN) has announced that the Board intends to increase the annualised dividend for 2024 by $0.20 to $3.10 per share, underlining the company’s confidence in its performance and cash generation. This takes into account other capital allocation priorities as well as previously announced acquisitions and business development.

Michel Demaré, Chair, said: “The Board is delighted to announce a 7% increase to the dividend, taking it to $3.10 per share. This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca’s investment proposition for shareholders.”

No changes are planned to the Company’s normal dividend payment timetable, which is:

·    First interim dividend – announced with half-year results and paid in September.

·    Second interim dividend – announced with full-year results and paid in March.

The Board also reaffirms its commitment to AstraZeneca’s progressive dividend policy.

Share on:

Latest Company News

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.

AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination

Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival.

AstraZeneca H1 2026 revenue rises 9% as growth momentum continues

AstraZeneca reported first-half 2026 revenue of $30.7 billion, up 6% at constant exchange rates, with core operating profit and core EPS both rising 11%. Growth in oncology and rare disease offset Farxiga and China headwinds. The company raised its interim dividend, secured 30 approvals, and reaffirmed full-year guidance and its $80 billion 2030 revenue goal.

Astrazeneca reports positive survival data for Sone-Ve in gastric cancer trial

Astrazeneca Plc has reported statistically significant overall survival results for Sone-Ve in the CLARITY-Gastric01 Phase III trial.

Astrazeneca secures EU approval for Etcamah in ER-positive breast cancer

Astrazeneca Plc has secured European Union approval for Etcamah in combination therapy for ER-positive, HER2-negative advanced breast cancer.

    Search